Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CTSG | P08311 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8089677 | 0.83 | MAPT (0.64) | SLC6A2SLC6A4SLC6A3KMT2AMEN1 | |
| SCHEMBL11817169 | 0.78 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KMT2AMEN1 | |
| SCHEMBL22411022 | 0.75 | MEN1 (0.44) | KMT2AMEN1MAPTLMNAL3MBTL1 | |
| SCHEMBL9877542 | 0.75 | KMT2A (0.42) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL6431344 | 0.75 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3KMT2AMAPT | |
| SCHEMBL21753317 | 0.74 | KMT2A (0.36) | KMT2AMEN1MAPTLMNA | |
| SCHEMBL10933135 | 0.74 | ALDH1A1 (0.55) | KMT2AMEN1MAPTCTSGCMA1 | |
| SCHEMBL8099209 | 0.73 | MAPT (0.55) | SLC6A2SLC6A4KMT2AMEN1MAPT | |
| SCHEMBL21770162 | 0.71 | VHL (0.37) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL6298790 | 0.71 | NOX4 (0.39) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| EP-1746091-A1 | Process for the preparation of 2-substituted 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one citrate | Pfizer Products Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1288208-B1 | Process for the preparation of 2-(4-Alkyl-1-Piperazinyl)-Benzaldehyde and -Benzylidenyl compounds by Nucleophilc Aromatic Substitution of 2-Fluorobenzaldehyde with 4-Alkyl-1-Piperazine in Water as Solvent | PFIZER PROD INC (US) | 2006-07-12 | — | — | EP | disclosed |
| US-6921760-B2 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1041070-B1 | Process for preparing cyclic thioamides | PFIZER PROD INC (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6627627-B2 | Useful as psychotherapeutic agents | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1339696-A1 | BENZYL(IDENE)-LACTAMS AND THEIR USE AS 5HT1-RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6608195-B2 | Dehalogenation, amination between o-fluorobenzaldehyde and a piperazine derivative followed by reaction with a 3-thio-morpholinone; serotonin 1 receptor agonists and antagonists | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| EP-0929528-B1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6562813-B2 | Psychological disorders; antiserotonin agents; headache therapy | PFIZER INC. | 2003-05-13 | — | — | US | disclosed |
| WO-2002046167-A1 | BENZYL (IDENE)-LACTAMS AND THEIR USE AS 5HT1-RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | disclosed |
| US-6388127-B1 | CYCLIZATION USING DEHYDRATION AGENT | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| JP-2000309581-A | PRODUCTION OF CYCLIC THIOAMIDES | PFIZER PROD INC | 2000-11-07 | — | — | JP | disclosed |
| EP-1041070-A1 | Process for preparing cyclic thioamides | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | SLC6A2 4180/4885SLC6A4 4503/4885SLC6A3 4113/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | SLC6A2 4351/4885SLC6A4 4583/4885SLC6A3 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.